Candriam SCA’s Terns Pharmaceuticals TERN Stock Holding History

Candriam SCA’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-631,636	Closed	-$33.3M	–	720
2026 Q1	$33.3M	Sell	631,636 -630,667	-50%	-$25.9M	0.17%	131
2025 Q4	$51M	Sell	1,262,303 -1,105,932	-47%	-$25.6M	0.25%	90
2025 Q3	$17.8M	Hold	2,368,235	–	–	0.09%	194
2025 Q2	$8.83M	Buy	2,368,235 +214,266	+10%	+$669K	0.05%	267
2025 Q1	$5.95M	Hold	2,153,969	–	–	0.04%	298
2024 Q4	$11.9M	Buy	+2,153,969	New	+$14.6M	0.07%	240

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Candriam SCA's TERN Position: Q2 2026 in Review

Candriam SCA sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 631,636 shares — an estimated $33.3M sold.

Candriam SCA first reported a position in TERN in Q4 2024 and held it in 6 quarters. The position peaked at $51M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Candriam SCA reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Candriam SCA sold 631,636 Terns Pharmaceuticals shares in Q2 2026, an estimated $33.3M.
Candriam SCA first reported a position in Terns Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Candriam SCA's Terns Pharmaceuticals position peaked at $51M in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.